



Agile Therapeutics  
Investor Relations Department  
101 Poor Farm Road  
Princeton, NJ 08540  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: AGRX**

Last Trade:	2.78
Trade Time:	12:25 PM ET Apr 20, 2018
Change:	-0.12 <span style="color: red;">▼</span> (-4.138%)
Day Range	2.78 - 2.91
52-Week Range	1.93 - 5.60
Volume	47,495


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

Our lead product candidate, Twirla® (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is based on our proprietary transdermal patch technology called Skinfusion® which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

## Stock Performance



### Press Releases [\[ View all \]](#)

- Mar 14, 2018*  
[Abstract on AG200-15 \(Twirla®\) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition](#)
- Mar 12, 2018*  
[Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results](#)
- Dec 22, 2017*  
[Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® \(AG200-15\) for the Prevention of Pregnancy](#)
- Nov 6, 2017*  
[Agile Therapeutics Reports Third Quarter 2017 Financial Results](#)
- Oct 31, 2017*  
[Agile Therapeutics Presents Additional Phase 3 SECURE Trial Results for Twirla® at the American Society for Reproductive Medicine \(ASRM\) Scientific Congress & Expo 2017](#)

### Financials [\[ View all \]](#)

- Mar 12, 2018*  
[Annual Report \(10-K\)](#)
- Apr 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 28, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)